View Older Stories View More Recent Stories
-
Sarepta Therapeutics (SRPT) Gains 5pct on UK Dosing Update in ENVISION
-
Sarepta Therapeutics (SRPT) Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
-
Sarepta Therapeutics (SRPT) Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
-
Morgan Stanley on Sarepta (SRPT): 'Elevidys Approval in Japan Further Confirms Favorable Benefit/Risk Profile'
-
Sarepta Therapeutics (SRPT) Announces Approval in Japan of ELEVIDYS
-
Evercore ISI Downgrades Sarepta Therapeutics (SRPT) to In Line, 'Near-Term Catalysts Won't Alleviate Key Concerns'
-
Sarepta Therapeutics (SRPT) PT Slashed to $137 at TD Cowen
-
Sarepta Therapeutics (SRPT) PT Lowered to $81 at Cantor Fitzgerald
-
Sarepta Therapeutics (SRPT) PT Lowered to $58 at RBC Capital as 'Elevidys Hits A Wall'
-
Sarepta Therapeutics (SRPT) PT Lowered to $120 at BMO Capital
-
Sarepta Therapeutics (SRPT) PT Lowered to $40 at H.C. Wainwright
-
Sarepta Therapeutics (SRPT) call put ratio 1 call to 1 put amid wide price movement
-
After-hours movers: AMD, Marvell Tech, Super Micro Computer and more
-
Sarepta Therapeutics (SRPT) Lowers Guidance
-
Sarepta Therapeutics (SRPT) Weakness Tied to FDA Appointee
-
Sarepta Therapeutics (SRPT) PT Slashed at Piper Sandler Following Survey Results
-
Sarepta Therapeutics (SRPT) Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
-
Wells Fargo Starts Sarepta Therapeutics (SRPT) at Overweight 'on DMD Commercial Opportunities'
-
Sarepta Therapeutics (SRPT) PT Lowered to $112 at Guggenheim
-
Sarepta Therapeutics (SRPT) PT Lowered to $184 at Oppenheimer
-
H.C. Wainwright Reiterates Neutral Rating on Sarepta Therapeutics (SRPT)
-
Barclays Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) Provides Update on ELEVIDYS
-
Sarepta Therapeutics (SRPT) PT Lowered to $183 at Needham
-
H.C. Wainwright Upgrades Sarepta Therapeutics (SRPT) to Neutral
-
RBC makes changes to its flagship 'Top 30 Global Ideas for 2025' list
-
UBS Reiterates Buy Rating on Sarepta Therapeutics (SRPT)
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Mizuho sees a compelling buying opportunity in this beaten-down biotech stock
-
Leerink Defending Sarepta Therapeutics (SRPT): 'the stock reaction for SRPT is overdone'
-
JPMorgan Comments on Sarepta Therapeutics (SRPT)
-
TD Cowen Reiterates Buy Rating on Sarepta Therapeutics (SRPT) following Elevidys death
-
Mizuho sees Sarepta Therapeutics (SRPT) sell-off on elevidys death 'likely an overreaction'
-
BofA Defending Sarepta Therapeutics (SRPT): 'Risk-benefit profile of Elevidys remains favorable despite death report'
-
Sarepta Therapeutics (SRPT) Shares Safety Update on ELEVIDYS
-
Sarepta Therapeutics (SRPT) Plunges 20% Pre-Open, Reason For Drop Unclear
-
Scotiabank Starts Sarepta Therapeutics (SRPT) at Sector Perform
-
Cantor Fitzgerald Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Sarepta Therapeutics (SRPT) files mixed shelf
-
RBC on Sarepta Therapeutics (SRPT): 'Overall We View Shares as Fundamentally Undervalued'; PT Lowered
-
Sarepta Therapeutics (SRPT) PT Lowered to $190 at Mizuho
-
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 36c
-
Deutsche Bank Starts Sarepta Therapeutics (SRPT) at Hold
-
Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)
-
BMO Capital Reiterates Outperform on Sarepta Therapeutics (SRPT) Following Part-2 Data from Elevidys PhIII
-
Morgan Stanley Reiterates Overweight Rating on Sarepta Therapeutics (SRPT)
-
Mizuho Reiterates Outperform Rating on Sarepta Therapeutics (SRPT)
-
H.C. Wainwright Reiterates Sell Rating on Sarepta Therapeutics (SRPT)
-
Piper Sandler on Sarepta Therapeutics (SRPT): 'SRPT Outperforms Revenue Guidance Driven By Elevidys'

